AlgaeCytes

About:

AlgaeCytes uses a photobioreactor system and freshwater algal strains to produce high purity Omega 3 oils EPA.

Website: http://algaecytes.com/

Top Investors: Deepbridge Capital, Federal Ministry for Economic Affairs and Energy (BMWi)

Description:

AlgaeCytes Limited has developed a proven innovative approach to the production of Omega 3 fatty acids, which are polyunsaturated fatty acids used in numerous bodily functions, such as controlling blood clotting and building cell membranes in the brain. Associated with many health benefits, including protection against heart disease and possibly stroke, new studies are identifying potential benefits for a wide range of conditions including cancer, inflammatory bowel disease and other auto-immune diseases such as lupus and rheumatoid arthritis.

Total Funding Amount:

16M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sandwich, Kent, United Kingdom

Founded Date:

2010-01-01

Contact Email:

admin(AT)algaecytes.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2022-01-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai